Zai Lab Ltd
$ 24.19
2.94%
17 Apr - close price
- Market Cap 2,654,041,000 USD
- Current Price $ 24.19
- High / Low $ 24.71 / 23.73
- Stock P/E N/A
- Book Value 6.47
- EPS -1.60
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.23 %
- 52 Week High 44.34
- 52 Week Low 15.96
About
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.
Analyst Target Price
$37.31
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-25 | 2024-11-12 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-07 | 2023-05-09 |
| Reported EPS | -0.46 | -0.33 | -0.37 | -0.45 | -0.8 | -0.42 | -0.8 | -0.5 | -1 | -0.71 | -1.25 | -0.51 |
| Estimated EPS | -0.3712 | -0.25 | -0.41 | -0.5475 | -0.6333 | -0.78 | -0.71 | -0.92 | -0.86 | -1.04 | -0.79 | -0.95 |
| Surprise | -0.0888 | -0.08 | 0.04 | 0.0975 | -0.1667 | 0.36 | -0.09 | 0.42 | -0.14 | 0.33 | -0.46 | 0.44 |
| Surprise Percentage | -23.9224% | -32% | 9.7561% | 17.8082% | -26.3224% | 46.1538% | -12.6761% | 45.6522% | -16.2791% | 31.7308% | -58.2278% | 46.3158% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.58 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZLAB
2026-04-17 18:40:09
Zai Lab announced new clinical data for zocilurtatug pelitecan (zoci), an investigational DLL3-targeting antibody-drug conjugate, showing rapid and robust intracranial responses in patients with small cell lung cancer (SCLC) and brain metastases. The data presented at AACR Annual Meeting 2026 revealed a 53.7% confirmed intracranial objective response rate (iORR) for SCLC with brain metastases, with specifically 62.5% at a 1.6 mg/kg dose, and promising activity with a 38.2% objective response rate in extrapulmonary neuroendocrine carcinomas (NECs). The company plans to advance zoci into three registration-enabling global Phase 3 studies by the end of the year for second-line-plus and first-line SCLC, and neuroendocrine carcinomas.
2026-04-17 13:40:10
Zai Lab Ltd has filed preliminary proxy materials for its 2026 annual general meeting, detailing proposals for director re-elections and auditor appointments. Shareholders will vote on executive compensation and mandates allowing the board to issue and repurchase up to 10% of the company’s shares and American Depositary Shares. This move highlights Zai Lab's commitment to complying with both U.S. and Hong Kong listing regulations.
2026-04-16 11:10:05
Boehringer Ingelheim and Zai Lab have announced a clinical collaboration to investigate a dual delta-like ligand 3 (DLL3)-targeting approach for patients with extensive-stage small cell lung cancer (ES-SCLC) and other neuroendocrine carcinomas (NECs). This Phase Ib/II study will combine Boehringer Ingelheim’s T-cell engager, obrixtamig, with Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci), to assess tolerability, safety, and early clinical activity. Both companies retain rights to their respective products, with Boehringer Ingelheim sponsoring and managing the clinical operations.
2026-04-13 21:09:19
This article examines Zai Lab Ltd (ZLAB), a Cayman Islands-incorporated biotech company listed on Nasdaq, focusing on its role for U.S. investors seeking exposure to China’s biotech market. Zai Lab operates through an asset-light model, in-licensing late-stage therapies for the Greater China market, primarily in oncology and immunology. The report discusses the company's business model, competitive advantages, future growth drivers, and risks associated with U.S.-China trade tensions and regulatory environments, offering insights for diversified portfolios.
2026-04-13 03:40:45
Zai Lab (ZLAB) is gaining attention due to progress in its Phase 3 DLLEVATE trial for small cell lung cancer and a new collaboration with Amgen. Despite a recent share price rebound, analysts suggest the stock is 58.2% undervalued with a fair value of $49.49, anticipating significant revenue growth and a shift to profitability. However, potential risks include competition and pricing pressures in China.
2026-04-08 23:09:50
Zai Lab's CFO, Yajing Chen, sold 853 American Depositary Shares (ADSs) on April 6, 2026, at an average price of $20.448 per ADS. This sale was automatically executed to cover taxes associated with the vesting of Restricted Share Units, indicating it was a tax-withholding transaction rather than a discretionary divestment. After the sale, Chen still directly holds 31,705 ADSs.
